Orchard Therapeutics has tasked Robin Kenselaar with accelerating growth of Lenmeldy, the world’s most expensive drug, promoting him to chief commercial officer after a year in which sales of the gene therapy fell short of expectations. More: Seeking fruitful Lenmeldy
read moreWhile the continued erosion of Biogen’s multiple sclerosis franchise and weaker-than-expected 2025 guidance doesn’t seem to be sitting well with investors, company leadership remains confident that a crop of new drugs can pick up the slack in the months and
read more
Potential treatment for multiple system atrophy shows promise More: Amlenetug receives FDA Fast Track Designation Source: News
read more
UCB’s BIMZELX reveals promising two-year data at EHSF 2025 More: Bimekizumab shows long-term efficacy in hidradenitis suppurativa Source: News
read moreSo far in 2025, the year’s biggest cultural events have served as launchpads for several of the industry’s latest cancer awareness campaigns. More: Lilly encourages women to 'take health into their own hands' with new breast cancer awareness ad Source:
read moreThe FDA earlier this month issued separate warning letters to Chinese drug ingredient firms Nuowei Chemistry and Innovation Pharmaceutical. The write-ups cover the quality control and testing shortfalls that led to both companies receiving U.S. import bans in late January.
read more© 1994 - 2026 B.M. Pharmaceuticals